Enfusion, Inc. (NYSE:ENFN) Sees Large Growth in Short Interest

Enfusion, Inc. (NYSE:ENFN) was the recipient of a significant growth in short interest in the month of January. As of January 15th, there was short interest totalling 711,700 shares, a growth of 27.9% from the December 31st total of 556,500 shares. Currently, 1.5% of the company’s stock are sold short. Based on an average trading volume of 695,500 shares, the short-interest ratio is presently 1.0 days.

Enfusion Stock Up 0.1 %

NYSE ENFN traded up $0.02 during trading hours on Friday, reaching $11.15. 551,512 shares of the company were exchanged, compared to its average volume of 1,169,221. The stock has a market capitalization of $1.43 billion, a P/E ratio of 278.69, a P/E/G ratio of 1.82 and a beta of 0.95. Enfusion has a 1 year low of $7.60 and a 1 year high of $11.38. The business’s 50 day simple moving average is $10.55 and its 200-day simple moving average is $9.45.

Insider Buying and Selling at Enfusion

In related news, CEO Oleg Movchan sold 2,771 shares of the firm’s stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $10.13, for a total value of $28,070.23. Following the transaction, the chief executive officer now owns 526,702 shares of the company’s stock, valued at approximately $5,335,491.26. This trade represents a 0.52 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Bradley Herring sold 24,443 shares of the business’s stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $10.61, for a total value of $259,340.23. Following the sale, the chief financial officer now directly owns 270,503 shares of the company’s stock, valued at $2,870,036.83. This represents a 8.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 57,367 shares of company stock valued at $591,335. Company insiders own 36.44% of the company’s stock.

Institutional Investors Weigh In On Enfusion

Large investors have recently modified their holdings of the stock. Geode Capital Management LLC increased its position in Enfusion by 7.3% in the third quarter. Geode Capital Management LLC now owns 1,029,366 shares of the company’s stock worth $9,770,000 after buying an additional 70,367 shares during the last quarter. Wellington Management Group LLP grew its stake in shares of Enfusion by 6.7% during the 3rd quarter. Wellington Management Group LLP now owns 976,296 shares of the company’s stock worth $9,265,000 after acquiring an additional 61,032 shares during the period. JPMorgan Chase & Co. increased its holdings in Enfusion by 612.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 208,022 shares of the company’s stock worth $1,974,000 after acquiring an additional 178,821 shares during the last quarter. Renaissance Technologies LLC raised its stake in Enfusion by 167.6% in the 2nd quarter. Renaissance Technologies LLC now owns 97,100 shares of the company’s stock valued at $827,000 after acquiring an additional 60,811 shares during the period. Finally, Barclays PLC lifted its holdings in Enfusion by 251.4% during the third quarter. Barclays PLC now owns 86,039 shares of the company’s stock valued at $817,000 after purchasing an additional 61,554 shares during the last quarter. Hedge funds and other institutional investors own 81.05% of the company’s stock.

Wall Street Analyst Weigh In

ENFN has been the subject of several recent analyst reports. Stifel Nicolaus upped their target price on shares of Enfusion from $11.00 to $13.00 and gave the stock a “buy” rating in a research note on Wednesday, December 18th. William Blair reiterated a “market perform” rating on shares of Enfusion in a research note on Monday, January 13th. Finally, Piper Sandler boosted their target price on Enfusion from $10.00 to $11.50 and gave the stock a “neutral” rating in a research note on Monday, December 23rd. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $10.50.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.